iwCLL 2025 | The ongoing rapid pace of advancement in CLL: practice-changing developments and promising therapies

What struck me from attending this year’s iwCLL meeting is the rapid pace of advancement in CLL. If you look over the last even just three, four years, we have seen multiple practice-changing clinical trials that have delivered novel therapies into the clinic. These include novel frontline treatment options, including AV with or without obinutuzumab based on the Phase III AMPLIFY study, which is added to our current armamentarium of VEN-O versus one of the covalent BTK inhibitors. These include novel approaches for the multiply relapsed/refractory patient populations, including pirtobrutinib and CAR T-cells with lisocabtagene maraleucel. And what struck me is that it seems that this is really only the beginning. We’ve got a number of different therapeutic options that are currently in late stage development, including in large phase three trials in the frontline settings. For example, the ongoing phase three CELESTIAL trial evaluating the sonrotoclax and zanubrutinib combination, ongoing studies, phase three studies, evaluating pirtobrutinib randomized against either ibrutinib in a mixed population of frontline and relapsed/refractory patients, as well as separately compared with bendamustine rituximab. We await data which we understand should be available at this year’s ASH meeting. And so this really just speaks to the rapid, ongoing pace of advancement in CLL.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.